IBI322

· Innovent Biologics (Suzhou) Co. Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IBI322, covering 2024-11-06 to 2024-11-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy [Phase 1]

See pricing